PPT-Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer
Author : min-jolicoeur | Published Date : 2018-11-08
This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Differentiating Among the CDK 4/6 Inhibi..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer: Transcript
This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. What’s Positive about Triple Negative Breast Cancer ? Julie R. Gralow, M.D. Jill Professor Endowed Professor of Breast Cancer Director, Breast Medical Oncology Seattle Cancer Care Alliance University of Washington School of Medicine Targeting endocrine-resistance pathways in breast cancer Clara Natoli, Chieti Endocrine responsive breast cancer Luminal A High expression of ER & ER-related genes Lower Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer An Interactive Oncology Grand Rounds Series. Joyce O’Shaughnessy, MD. Chair, Breast Cancer Research Program. Baylor Charles A Sammons Cancer Center. Celebrating Women Chair in Breast Cancer Research. Julie R. Gralow, M.D.. Director, Breast Medical Oncology. Jill Bennett Endowed Professor of Breast Cancer. Professor, Global Health. University of Washington School of Medicine. Fred Hutchinson Cancer Research Center. VeruInc Oncology Biopharmaceutical Company Focused on Prostate Cancer and Breast CancerVeru Corporate PresentationJefferies Virtual Healthcare ConferenceJune 1 June 4 2021Forward looking statements2Th Breast Cancer : How important is it? . It is the most common cancer among women in lower-and-middle-income in Asian countries. . Its cost to society in terms of . - use of healthcare resources . tablet the next day.Aromatase inhibitors can interact with other medications specialist or doctor.Always tell any other doctor, dentist or pharmacist inhibitor.oestrogen in the body, it is possible to HOPC. Mrs GV is a 78 year old women who presented to Cabrini ED with acute dyspnoea is the setting of recent malignant pleural effusion in the setting of Metastatic Breast Ca.. Nov 2010: Self Detected left breast lump (AJCC Stage . Background of lower back pain for 3/12 . No past medical Hx.. Social Hx: . Married 2 small children, works in hospital admin. Regular Menstrual periods. Family Hx: . Aunt: Breast Ca 55. Aims. O/E:. Palpable LN under the right axilla. Key recommendations. 1. National and local workforce planning is essential. Health Education England and all Cancer Alliances should urgently ensure there are enough healthcare professionals to deliver high-quality and timely diagnosis, treatment and care to local women.. Elana Plotkin, CMP-HC. 1. , Marianne Gandee, MA. 2. , Lorna Lucas , MSM. 1. 1 Association of Community Cancer Centers, Provider Education, Rockville, MD, USA 2 Association of Community Cancer Centers, Development, Rockville, MD, USA. Jo Anne Zujewski, M.D.. June 2019. Thimphu. , Bhutan. Define the breast cancer. Is the cancer operable?. Stage 1: systemic therapy after surgery (and radiation if breast conservation). Stage 2: systemic therapy before or after therapy.
Download Document
Here is the link to download the presentation.
"Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents